ValuEngine Upgrades Calithera Biosciences (CALA) to Hold

Calithera Biosciences (NASDAQ:CALA) was upgraded by investment analysts at ValuEngine from a “sell” rating to a “hold” rating in a report released on Wednesday.

CALA has been the topic of several other research reports. Leerink Swann reaffirmed an “outperform” rating on shares of Calithera Biosciences in a research note on Friday, April 6th. Zacks Investment Research raised Calithera Biosciences from a “sell” rating to a “hold” rating in a research note on Tuesday, May 15th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $16.50.

NASDAQ CALA opened at $5.30 on Wednesday. The firm has a market cap of $178.33 million, a price-to-earnings ratio of -6.31 and a beta of 2.53. Calithera Biosciences has a fifty-two week low of $4.70 and a fifty-two week high of $20.05.



Calithera Biosciences (NASDAQ:CALA) last announced its quarterly earnings results on Thursday, May 10th. The biotechnology company reported ($0.37) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.32) by ($0.05). Calithera Biosciences had a negative net margin of 131.51% and a negative return on equity of 22.92%. The business had revenue of $5.19 million during the quarter, compared to analyst estimates of $7.28 million. equities analysts forecast that Calithera Biosciences will post -1.4 EPS for the current fiscal year.

Several institutional investors have recently made changes to their positions in the company. Schwab Charles Investment Management Inc. lifted its stake in Calithera Biosciences by 56.8% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 112,235 shares of the biotechnology company’s stock worth $938,000 after acquiring an additional 40,635 shares in the last quarter. American Century Companies Inc. lifted its stake in Calithera Biosciences by 42.0% during the 4th quarter. American Century Companies Inc. now owns 603,119 shares of the biotechnology company’s stock worth $5,036,000 after acquiring an additional 178,367 shares in the last quarter. Swiss National Bank acquired a new position in Calithera Biosciences during the 4th quarter worth about $378,000. Wells Fargo & Company MN lifted its stake in Calithera Biosciences by 84.0% during the 4th quarter. Wells Fargo & Company MN now owns 62,077 shares of the biotechnology company’s stock worth $519,000 after acquiring an additional 28,335 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in Calithera Biosciences by 20.6% during the 4th quarter. Bank of New York Mellon Corp now owns 132,678 shares of the biotechnology company’s stock worth $1,108,000 after acquiring an additional 22,688 shares in the last quarter. 62.82% of the stock is currently owned by institutional investors and hedge funds.

About Calithera Biosciences

Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply